India, April 2 -- The US Food and Drug Administration on Wednesday approved Foundayo, a new GLP-1 weight loss pill made by Eli Lilly, adding another option to the rapidly growing arsenal of obesity therapies. The orforglipron pill, called Foundayo, is the second GLP-1 pill approved for weight loss, coming just months after the FDA greenlit Novo Nordisk's Wegovy pill.

Eli Lilly already sells the injectable GLP-1 drugs Zepbound for obesity and Mounjaro for diabetes. Together with rival drugs Wegovy and Ozempic, these medications have transformed weight-loss and diabetes treatment, with millions of people taking them.

The US Food and Drug Administration approved the second GLP-1 pill for weight loss, adding another option to a rapidly grow...